Relapsed/refractory patients

Two major highlights from ASH for patients with relapsed/refractory multiple myeloma

L: English

The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Miles Prince, Peter MacCallum Cancer Centre, Melbourne, AU, presents two major highlights from ASH for patients with relapsed/refractory multiple myeloma.

Miles Prince talks about the key topics that have been presented in ASH 2019. He describes the key principles of CAR T therapy in myeloma, and discusses the emerging CAR T therapies around the world, and the efficacy of CAR T in different patient populations. Miles Prince concludes by summarizing the results of studies that examined monoclonal antibodies in both the transplant eligible and ineligible setting.